Latest Healthcare It News

Oakridge International Limited reports a strong quarterly performance driven by increased contracted orders, strategic partnerships, and technological innovation, positioning the company for sustained growth into 2025.

Excite Technology Services has achieved positive EBITDA in December 2024, driven by strong revenue growth and record customer receipts, notably from its Digital Forensics division and the integration of CDFS.

Arovella Therapeutics has bolstered its financial position with a $20 million placement, fully funding the Phase 1 clinical trial of its lead CAR-iNKT therapy, ALA-101, targeting CD19-positive blood cancers. The company also established a Clinical Advisory Board and anticipates key regulatory and clinical milestones in 2025.

HeraMED reports a surge in its HeraCARE platform users and secures $4.1 million in new funding, underpinning its expansion in the US maternity care market and integration with major health systems.

dorsaVi reported a modest 1.9% rise in sales revenue to $330k in Q2 FY25, launched its AI-powered Video AI movement analysis platform, and initiated a blockchain integration partnership to enhance data security.

IMEXHS Limited reported a robust 34% increase in FY24 revenue to $26.5 million, driven by new contracts in Colombia and Peru that boosted its Annual Recurring Revenue to $30 million. Despite a slight EBITDA shortfall due to a bad debt expense, the company highlighted operational improvements and strengthened its regional footprint.

Credit Clear Limited has reported a robust first half of FY25 with record revenue and a significant rise in profitability, reaffirming its full-year guidance amid strong client acquisition.

ResMed Inc. has announced a quarterly ordinary dividend of USD 0.053 per share for holders of its ASX-listed Chess Depositary Instruments, with payments scheduled for March 2025.

Enlitic reported a robust 41.1% increase in quarterly revenue alongside the completion of its strategic acquisition of Laitek, positioning the company for operational cash flow break-even by the end of 2025.

Nido Education Limited has appointed Adam Lai, former PwC Sydney Managing Partner, as its new CEO starting February 2025, signaling a strategic push for significant expansion over the next five to eight years.

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

Control Bionics has delivered its strongest US sales quarter in years, nearing US$1 million in revenue, while broadening its market footprint with new commercial agreements and cost optimizations.